Former NICE Exec Proposes New UK Fund For ‘High-Impact’ Drugs
Executive Summary
Some of the rebates paid by drug companies to the government on their sales of medicines could be placed in a central fund to pay for drugs of “demonstrable benefit,” according to Andrew Dillon.
You may also be interested in...
ABPI’s 6.88% Rebate Proposal ‘Completely Unaffordable,’ Says UK Health Dept
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.
Mixed Support For ABPI's UK Price Scheme Proposals
The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.
Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.